Overview

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

The primary objective of this pilot study is to assess the feasibility of mobilizing PD-1+ T cells to the peripheral blood after a single treatment with tremelimumab/durvalumab in patients with treatment naïve metastatic melanoma.

Phase:

Early Phase 1

Details

Lead Sponsor:

Yale University

Treatments:

Antibodies, Monoclonal
Durvalumab
Ipilimumab
Nivolumab
Tremelimumab